Theratechnologies (THTX) Price & Analysis

Compare

232 Followers

THTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.12 - $3.40

Previous CloseN/A

Volume43.44K

Average Volume (3M)615.24K

Market Cap

$147.41M

Enterprise Value$225.52M

Total Cash (Recent Filing)$9.92M

Total Debt (Recent Filing)$43.62M

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Oct 09, 2025

EPS Estimate

0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding45,980,020

10 Day Avg. Volume1,146,282

30 Day Avg. Volume615,241

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.53

Enterprise Value/Revenue2.67

Enterprise Value/Gross Profit3.44

Enterprise Value/Ebitda110.12

Forecast

1Y Price Target

$3.24

Price Target Upside-4.42% Downside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Acquisition PremiumThe acquisition offer from Future Pak represents a 126% premium to the closing price before the announcement, indicating a significant value proposition for shareholders.

Long-term SecurityPatent protection for EGRIFTA WR extends into 2033, providing long-term security for the product.

Sales GrowthThe launch of EGRIFTA WR is expected to allow the company to increase sales growth and maintain positive momentum.

Bears Say

Acquisition UncertaintyThere is skepticism about the success of Future Pak's acquisition offer, and it is likely to fall through despite recognizing the value of the EGRIFTA franchise.

Financial Performance2Q25 fully adjusted EPS of ($0.09) missed consensus expectations of ($0.01), which may indicate financial challenges.

Revenue ImpactAn expected one-time reduction in revenue due to a supply disruption resulted in a $10M — $12M decrease for FY25.

Theratechnologies News

Theratechnologies shareholders approve proposed acquisition by Future Pak

Theratechnologies (THTX) announced that its shareholders have approved the previously announced plan of arrangement under Chapter XVI –...

18d ago

THTX

Theratechnologies announces availability of EGRIFTA WR

Theratechnologies (THTX) announced the availability of EGRIFTA WR for injection for the reduction of excess abdominal fat in...

25d ago

THTX

Theratechnologies says ISS, Glass Lewis recommend vote ‘FOR’ Future Pak plan

Theratechnologies (THTX) announces that two leading independent proxy advisory firms, Institutional Shareholders Services and Glass Lewis & Co.,...

28d ago

THTX

Theratechnologies Completes Acquisition by Future Pak

Theratechnologies ( ($TSE:TH) ) has provided an announcement. Theratechnologies has completed its acquisition by Future Pak, with all...

5d ago

THTX

Theratechnologies Receives Court Approval for Acquisition by Future Pak

Theratechnologies ( ($TSE:TH) ) has shared an update. Theratechnologies has received final court approval for its acquisition by...

14d ago

THTX

Theratechnologies Shareholders Approve Acquisition by Future Pak Affiliate

Theratechnologies ( ($TSE:TH) ) just unveiled an announcement. Theratechnologies Inc. has announced that its shareholders have overwhelmingly approved...

18d ago

THTX

Theratechnologies Launches EGRIFTA WR™ for HIV-Related Lipodystrophy

Theratechnologies ( ($TSE:TH) ) has issued an update. Theratechnologies has announced the availability of EGRIFTA WR™, a new...

25d ago

THTX

Theratechnologies Gains Support for Future Pak Acquisition

An update from Theratechnologies ( ($TSE:TH) ) is now available. Theratechnologies Inc. announced that independent proxy advisory firms...

28d ago

THTX

Theratechnologies Announces Acquisition by CB Biotechnology with Significant Shareholder Premium

Theratechnologies ( ($TSE:TH) ) just unveiled an update. Theratechnologies Inc. has announced the filing of special meeting materials...

1M ago

THTX

Theratechnologies receives interim order in acquisition by CB Biotechnology

Theratechnologies (THTX) has filed and is in the process of mailing the management proxy circular and related materials...

1M ago

THTX

Theratechnologies’ Ibalizumab Study: A Potential Game-Changer for Multidrug-Resistant HIV

Theratechnologies (($THTX)), Theratechnologies (TH) (($TSE:TH)) announced an update on their ongoing clinical study. Study Overview: Theratechnologies is conducting...

2M ago

THTX

Theratechnologies Announces Special Shareholder Meeting for September 2025

Theratechnologies ( ($TSE:TH) ) just unveiled an update. Theratechnologies Inc. announced a special meeting of shareholders scheduled for...

2M ago

THTX

Theratechnologies Announces Acquisition Agreement with CB Biotechnology

Theratechnologies ( ($TSE:TH) ) has shared an announcement. On July 2, 2025, Theratechnologies Inc. announced a binding agreement...

3M ago

THTX

Theratechnologies Reports Q2 2025 Earnings and Acquisition

Theratechnologies ( ($THTX) ) has released its Q2 earnings. Here is a breakdown of the information Theratechnologies presented...

3M ago

THTX

THTX FAQ

What was Theratechnologies’s price range in the past 12 months?

Theratechnologies lowest stock price was $1.12 and its highest was $3.40 in the past 12 months.

What is Theratechnologies’s market cap?

Theratechnologies’s market cap is $147.41M.

When is Theratechnologies’s upcoming earnings report date?

Theratechnologies’s upcoming earnings report date is Oct 09, 2025 which is in 9 days.

How were Theratechnologies’s earnings last quarter?

Theratechnologies released its earnings results on Jul 09, 2025. The company reported -$0.091 earnings per share for the quarter, missing the consensus estimate of -$0.015 by -$0.076.

Is Theratechnologies overvalued?

According to Wall Street analysts Theratechnologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Theratechnologies pay dividends?

Theratechnologies does not currently pay dividends.

What is Theratechnologies’s EPS estimate?

Theratechnologies’s EPS estimate is 0.04.

How many shares outstanding does Theratechnologies have?

Theratechnologies has 45,980,020 shares outstanding.

What happened to Theratechnologies’s price movement after its last earnings report?

Theratechnologies reported an EPS of -$0.091 in its last earnings report, missing expectations of -$0.015. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Theratechnologies?

Currently, no hedge funds are holding shares in THTX

Theratechnologies Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-26.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.